C12N 5/0638
Cytotoxic t lymphocytes [ctl] or lymphokine activated killer cells [lak]
Official title: {Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]}
C12N5/0638 (Cytotoxic t lymphocytes [ctl] or lymphokine activated killer cells [lak]) appears on 1,020 US grants and 1,839 published applications in this corpus.
Search patents in C12N- Granted patents
- 1,020
- Published applications
- 1,839
- Assignees
- 558
- Inventors
- 2,219
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1995 | 1 | 0 |
| 1996 | 0 | 0 |
| 1997 | 0 | 0 |
| 1998 | 0 | 0 |
| 1999 | 0 | 0 |
| 2000 | 0 | 0 |
| 2001 | 1 | 0 |
| 2002 | 0 | 0 |
| 2003 | 1 | 0 |
| 2004 | 0 | 0 |
| 2005 | 0 | 1 |
| 2006 | 0 | 1 |
| 2007 | 0 | 1 |
| 2008 | 0 | 5 |
| 2009 | 1 | 3 |
| 2010 | 1 | 8 |
| 2011 | 2 | 23 |
| 2012 | 5 | 17 |
| 2013 | 9 | 20 |
| 2014 | 11 | 26 |
| 2015 | 24 | 43 |
| 2016 | 16 | 73 |
| 2017 | 24 | 100 |
| 2018 | 90 | 131 |
| 2019 | 121 | 228 |
| 2020 | 114 | 163 |
| 2021 | 115 | 225 |
| 2022 | 109 | 266 |
| 2023 | 82 | 183 |
| 2024 | 128 | 130 |
| 2025 | 112 | 115 |
| 2026 | 53 | 77 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- CCR4 targeted chimeric antigen receptor modified T cells for treatment of CCR4 positive malignancies6 Oct 2026US 12,753,219 B2City of Hope
- FOXM1-derived peptide, and vaccine including same29 Sep 2026US 12,747,265 B2Oncotherapy Science, Inc.
- Modulation of expression of genes related to T cell exhaustion29 Sep 2026US 12,747,431 B2The Trustees of the University of Pennsylvania
- Chimeric antigen receptors with CD20 safety switch22 Sep 2026US 12,742,001 B2St. Jude Children?S Research Hospital
- Fixed ratio ex vivo activated mixed lymphocyte products for use in the treatment of cancer22 Sep 2026US 12,742,153 B2Children's National Medical Center
- Cd4+ cytotoxic t cells and methods of use thereof8 Oct 2026US 2026/0308522 A1Dana-Farber Cancer Institute, Inc.
- Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy1 Oct 2026US 2026/0293881 A1Iovance Biotherapeutics, Inc.
- Systems and methods for cell culturing24 Sep 2026US 2026/0286267 A1Flaskworks, LLC
- Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy17 Sep 2026US 2026/0272985 A1Iovance Biotherapeutics, Inc.
- Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy17 Sep 2026US 2026/0272986 A1Iovance Biotherapeutics, Inc.
Most cited
By later US patents
- Immunotherapy against several tumors, such as lung cancer, including NSCLC198US 10,071,148 B2Immatics Biotechnologies GmbH · 2018
- Methods of cell culture for adoptive cell therapy156US 8,956,860 B22015
- Immunotherapy against several tumors, such as lung cancer, including NSCLC131US 9,943,579 B2Immatics Biotechnologies GmbH · 2018
- Immunogenic epitope for immunotherapy117US 8,080,634 B2Immatics Biotechnologies GmbH · 2011
- Immunogenic epitopes for immunotherapy113US 9,511,128 B2Immatics Biotechnologies GmbH · 2016